GO:0071548 response to dexamethasone: Glucocorticoid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071548 response to dexamethasone is defined as any process that results in a change in state or activity of a cell or an organism as a result of a dexamethasone stimulus.
• Dexamethasone is a synthetic glucocorticoid widely used to probe glucocorticoid receptor (NR3C1) signaling, and the response is context-dependent across tissues.
• Clinically, dexamethasone response varies between individuals, as shown by differential intraocular pressure responses in perfused cadaveric eyes and by survival prediction in tuberculous meningitis.
• Dexamethasone modulates diverse physiological outputs including ovarian response to gonadotrophins, insulin release, airway inflammation, epithelial differentiation, and adrenal androgen secretion.
• Key genes and proteins in this response include NR3C1, FKBP5, TSC22D3, NFKB1, and others that mediate transcriptional and non-transcriptional glucocorticoid effects.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of genes involved in the dexamethasone response.
Description
GO:0071548 response to dexamethasone is a biological process ontology term that captures any change in cellular or organismal state or activity following exposure to dexamethasone, a synthetic glucocorticoid. This term is essential for annotating experiments that use dexamethasone as a tool to interrogate glucocorticoid receptor signaling, stress responses, immune modulation, and metabolic regulation. Because dexamethasone is a potent and widely prescribed corticosteroid, understanding the genes and pathways that mediate its effects has direct clinical relevance. The response is highly context-dependent: in perfused Indian cadaveric eyes, dexamethasone treatment produced differential intraocular pressure responses, highlighting inter-individual variability. In tuberculous meningitis, elevated cerebrospinal fluid cytokine levels predicted survival in response to dexamethasone, linking inflammatory status to treatment outcome. In reproductive medicine, low-dose dexamethasone augmented the ovarian response to exogenous gonadotrophins and reduced cycle cancellation rates in a standard IVF programme. These examples illustrate that GO:0071548 encompasses a broad range of physiological and pathological processes. Researchers studying this term aim to identify the molecular mediators, regulatory mechanisms, and disease contexts in which dexamethasone response is critical. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0071548, its associated genes, experimental models, and methods for investigation.
response to dexamethasone At A Glance
| GO ID | GO:0071548 |
|---|---|
| GO term | response to dexamethasone |
| Ontology | biological_process |
| Synonym | response to dexamethasone stimulus |
| Major function | Mediates cellular and organismal changes in response to dexamethasone, a synthetic glucocorticoid |
| Related stimuli | Dexamethasone, glucocorticoids, stress hormones |
| Typical readouts | Gene expression, enzyme production, secretion, movement, physiological changes |
| Disease relevance | Inflammatory diseases, cancer, metabolic disorders, reproductive disorders, ocular hypertension |
| Experimental models | Cell lines, animal models, perfused organs, clinical samples |
What Is GO:0071548?
According to the Gene Ontology, GO:0071548 response to dexamethasone is defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dexamethasone stimulus. The synonym response to dexamethasone stimulus is also used. This term is a biological process and is typically used to annotate gene products whose activity or expression is altered upon dexamethasone exposure. It does not specify a particular signaling pathway or outcome; rather, it captures the broad set of responses triggered by dexamethasone, which can include transcriptional changes, metabolic shifts, and physiological adaptations.
Why Is response to dexamethasone Important in Cell Biology?
GO:0071548 is important because dexamethasone is a cornerstone therapeutic agent for inflammatory, autoimmune, and neoplastic conditions, and its effects are mediated by a complex network of genes and pathways. Understanding the response to dexamethasone at the molecular level can reveal biomarkers of sensitivity or resistance, guide personalized dosing, and identify novel drug targets. For example, differential intraocular pressure responses to dexamethasone in perfused cadaveric eyes suggest that genetic or physiological factors influence the response. In tuberculous meningitis, cerebrospinal fluid cytokine levels predicted survival in response to dexamethasone, underscoring the interplay between inflammation and treatment outcome. Low-dose dexamethasone augmented ovarian response to gonadotrophins in IVF, demonstrating its utility in reproductive medicine. Conversely, dexamethasone treatment failed to increase arginine-induced insulin release in healthy subjects with low insulin response, indicating context-dependent metabolic effects. In allergic airway disease models, dexamethasone reduced airway hyperresponsiveness and inflammatory cell responses. Dexamethasone also accelerated differentiation of A6 epithelia and increased response to vasopressin. In hirsutism, dexamethasone suppressed adrenal androgens, linking the response to endocrine regulation. Thus, GO:0071548 is central to understanding glucocorticoid biology and its therapeutic applications.
• Dexamethasone is used to treat inflammatory and autoimmune diseases, and the response is mediated by genes annotated to GO:0071548.
• In tuberculous meningitis, dexamethasone response is associated with survival and cytokine levels.
• Dexamethasone modulates ovarian response to gonadotrophins, affecting IVF outcomes.
• Dexamethasone can influence insulin release, with variable effects depending on individual insulin response.
• In allergic airway disease, dexamethasone reduces hyperresponsiveness and inflammation.
• Dexamethasone accelerates epithelial differentiation and enhances vasopressin response.
• Dexamethasone suppresses adrenal androgen production in hirsutism.
• Differential intraocular pressure responses to dexamethasone highlight inter-individual variability.
• The response involves transcriptional regulation by the glucocorticoid receptor NR3C1 and its cofactors.
• CRISPR screens can identify genes that modify the dexamethasone response, enabling target discovery.
What Happens During response to dexamethasone?
Dexamethasone Binding and Glucocorticoid Receptor Activation
In simple terms: Dexamethasone enters the cell and binds to the glucocorticoid receptor, which then moves into the nucleus to change gene expression.
Dexamethasone is a synthetic glucocorticoid that diffuses across the plasma membrane and binds to the glucocorticoid receptor (NR3C1) in the cytoplasm. Upon binding, NR3C1 undergoes a conformational change, dissociates from heat shock proteins, and translocates to the nucleus. There, it binds to glucocorticoid response elements (GREs) in DNA to activate or repress target genes. This initial step is the cornerstone of the cellular response to dexamethasone and is required for downstream effects such as changes in enzyme production, secretion, and movement.
Transcriptional Regulation of Target Genes
In simple terms: The activated receptor turns genes on or off, leading to changes in proteins that control cell behavior.
Activated NR3C1 modulates the transcription of numerous target genes, including FKBP5, TSC22D3 (GILZ), and NFKB1. These genes influence inflammation, metabolism, and cell survival. For example, dexamethasone treatment altered cytokine levels in tuberculous meningitis, reflecting transcriptional changes in immune cells. In allergic airway disease models, dexamethasone reduced inflammatory cell responses, likely through transcriptional repression of pro-inflammatory genes. The specific set of genes regulated depends on cell type and context, which explains the diverse physiological outcomes associated with GO:0071548.
Non-Transcriptional Effects and Rapid Signaling
In simple terms: Dexamethasone can also cause quick changes in cell signaling without altering gene expression.
In addition to transcriptional effects, dexamethasone can trigger rapid non-genomic signaling events, such as activation of kinases and changes in ion transport. For instance, dexamethasone accelerated differentiation of A6 epithelia and increased the response to vasopressin, which may involve both transcriptional and non-transcriptional mechanisms. In hirsutism, dexamethasone suppressed adrenal androgens, likely through rapid feedback inhibition of the hypothalamic-pituitary-adrenal axis. These rapid effects contribute to the overall response to dexamethasone and can occur within minutes.
Physiological and Pathological Outcomes
In simple terms: The cellular changes lead to measurable effects in the body, such as reduced inflammation or altered hormone levels.
The integrated response to dexamethasone manifests as physiological changes. In perfused cadaveric eyes, dexamethasone altered intraocular pressure, with differential responses among individuals. In IVF, low-dose dexamethasone augmented ovarian response to gonadotrophins, improving cycle outcomes. In healthy subjects with low insulin response, dexamethasone failed to increase arginine-induced insulin release, indicating that the response is context-dependent. In allergic airway disease, dexamethasone reduced hyperresponsiveness and inflammatory cell infiltration. These outcomes reflect the complex interplay of genes and pathways annotated to GO:0071548.
Key Genes Involved in GO:0071548 response to dexamethasone
The following genes and proteins are central to the response to dexamethasone, based on their roles in glucocorticoid signaling, inflammation, metabolism, and clinical responses.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR3C1 | Glucocorticoid receptor; binds dexamethasone and regulates transcription | Primary mediator of dexamethasone response; target for KO and point mutation studies |
| FKBP5 | Co-chaperone that regulates glucocorticoid receptor sensitivity | Modulates dexamethasone response; biomarker in stress-related disorders |
| TSC22D3 | Glucocorticoid-induced leucine zipper; anti-inflammatory mediator | Key effector of dexamethasone's anti-inflammatory effects |
| NFKB1 | Transcription factor repressed by glucocorticoid receptor | Mediates anti-inflammatory effects of dexamethasone |
| IL6 | Pro-inflammatory cytokine suppressed by dexamethasone | Readout of dexamethasone response in inflammation models |
| TNF | Pro-inflammatory cytokine inhibited by dexamethasone | Marker of dexamethasone efficacy in inflammatory diseases |
| IL1B | Cytokine modulated by dexamethasone | Involved in inflammatory responses; target for KO studies |
| CXCL8 | Chemokine suppressed by dexamethasone | Neutrophil recruitment; readout in airway inflammation |
| ANXA1 | Annexin A1; mediates anti-inflammatory effects of glucocorticoids | Effector of dexamethasone in resolving inflammation |
| SGK1 | Serum/glucocorticoid-regulated kinase 1 | Ion transport and cell survival; induced by dexamethasone |
| DUSP1 | Dual specificity phosphatase 1; inhibits MAPK signaling | Mediates anti-inflammatory effects of dexamethasone |
| PER1 | Period circadian regulator 1; regulated by glucocorticoids | Links dexamethasone response to circadian rhythms |
| CRH | Corticotropin-releasing hormone; suppressed by dexamethasone | Feedback regulation of HPA axis; used in dexamethasone suppression test |
| POMC | Proopiomelanocortin; precursor of ACTH; suppressed by dexamethasone | Endocrine readout of dexamethasone response |
| AVP | Arginine vasopressin; modulated by dexamethasone | Regulates water balance; response studied in A6 epithelia |
| AQP2 | Aquaporin 2; water channel regulated by vasopressin and dexamethasone | Epithelial differentiation and water transport |
| CYP17A1 | Steroid 17-alpha-hydroxylase; involved in androgen synthesis | Suppressed by dexamethasone in hirsutism |
| STAR | Steroidogenic acute regulatory protein | Cholesterol transport; regulated by dexamethasone in adrenal cells |
How Is response to dexamethasone Regulated?
The response to dexamethasone is regulated at multiple levels. The glucocorticoid receptor NR3C1 is the primary regulator, and its activity is modulated by co-chaperones such as FKBP5, which can alter ligand sensitivity. Negative feedback loops involving CRH and POMC suppress the hypothalamic-pituitary-adrenal axis, as demonstrated by dexamethasone suppression of adrenal androgens in hirsutism. Inflammatory signaling pathways, including NF-kB and MAPK, are inhibited by dexamethasone-induced proteins such as DUSP1 and TSC22D3, contributing to anti-inflammatory effects. Additionally, circadian regulators like PER1 can influence the response. The context-dependent nature of dexamethasone response is highlighted by differential effects on insulin release and intraocular pressure, suggesting that genetic and physiological factors modulate the pathway.
response to dexamethasone and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NR3C1 | Glucocorticoid resistance, inflammatory diseases | Knockout or point mutation in cell lines; patient-derived cells |
| FKBP5 | Stress-related disorders, depression | Knock-in of risk variants; overexpression in neuronal cells |
| TSC22D3 | Inflammatory diseases, autoimmune disorders | Knockout mice; reporter cell lines |
| NFKB1 | Chronic inflammation, cancer | Knockout and overexpression in immune cells |
| CYP17A1 | Hirsutism, adrenal hyperplasia | Knockout in adrenal cell lines; patient mutations |
Inflammatory and Infectious Diseases
Dexamethasone is widely used to treat inflammatory conditions, and the response is critical for therapeutic efficacy. In tuberculous meningitis, elevated cerebrospinal fluid cytokine levels predicted survival in response to dexamethasone, indicating that the inflammatory milieu influences treatment outcome. In allergic airway disease models, dexamethasone reduced airway hyperresponsiveness and inflammatory cell responses, demonstrating its anti-inflammatory action. These findings link GO:0071548 to infectious and allergic diseases.
Metabolic and Endocrine Disorders
Dexamethasone affects glucose metabolism and hormone secretion. In healthy subjects with low insulin response, dexamethasone treatment failed to increase arginine-induced insulin release, suggesting that the response varies with individual metabolic status. In hirsutism, dexamethasone suppressed adrenal androgen production, linking the response to endocrine regulation. These examples show that GO:0071548 is relevant to metabolic and endocrine disorders.
Reproductive Medicine and Ocular Diseases
Low-dose dexamethasone augmented the ovarian response to exogenous gonadotrophins and reduced cycle cancellation in IVF, highlighting its role in reproductive medicine. In perfused cadaveric eyes, differential intraocular pressure responses to dexamethasone were observed, which may have implications for steroid-induced ocular hypertension. These clinical contexts demonstrate the broad impact of the dexamethasone response.
From response to dexamethasone-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NR3C1 mediate dexamethasone-induced gene expression? | NR3C1 knockout cell line (e.g., HEK293 or A549) with dexamethasone treatment |
| How do point mutations in NR3C1 affect ligand binding? | Knock-in of specific NR3C1 mutations in cell lines; luciferase reporter assays |
| What is the role of FKBP5 in modulating dexamethasone sensitivity? | FKBP5 overexpression and knockout in neuronal or immune cells |
| Can TSC22D3 knockout abolish anti-inflammatory effects of dexamethasone? | TSC22D3 knockout macrophages; cytokine profiling |
| Does a tagged NR3C1 knock-in reveal dynamic localization? | CRISPR knock-in of fluorescent tag (e.g., GFP) into NR3C1 locus; live-cell imaging |
| Which genes modify dexamethasone response in a genome-wide screen? | CRISPR knockout library screening in cells treated with dexamethasone |
How to Study the response to dexamethasone Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify dexamethasone-regulated genes and pathways |
| qPCR | Expression of specific genes | Validate candidate genes like FKBP5 or TSC22D3 |
| Proteomics | Protein abundance and modifications | Detect non-transcriptional effects and novel mediators |
| CRISPR knockout screening | Genes required for or modifying dexamethasone response | Discover resistance or sensitivity genes |
| Live-cell imaging | NR3C1 nuclear translocation dynamics | Study real-time glucocorticoid receptor trafficking |
| Luciferase reporter assay | Transcriptional activity of GREs | Measure NR3C1 transactivation capacity |
| Cytokine profiling | Secretion of inflammatory mediators | Assess anti-inflammatory effects of dexamethasone |
| Intraocular pressure measurement | Physiological response in perfused eyes | Study differential steroid response |
Transcriptomic Profiling
RNA sequencing (RNA-seq) is widely used to measure changes in gene expression following dexamethasone treatment. This method can identify genes and pathways annotated to GO:0071548, such as FKBP5 and TSC22D3, and reveal context-specific responses. Quantitative PCR can validate candidate genes.
Proteomic and Phosphoproteomic Analysis
Mass spectrometry-based proteomics can quantify protein abundance and post-translational modifications after dexamethasone exposure. This is useful for detecting non-transcriptional effects and identifying novel mediators of the response.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that modify the dexamethasone response. For example, screening in the presence of dexamethasone can reveal synthetic lethal interactions or resistance mechanisms, providing causal insights into GO:0071548.
Imaging and Functional Assays
Live-cell imaging of fluorescently tagged NR3C1 can track nuclear translocation. Functional assays such as intraocular pressure measurement in perfused eyes or insulin release assays provide physiological readouts of the dexamethasone response.
How CRISPR Can Be Used to Study GO:0071548 response to dexamethasone
Knockout
CRISPR knockout of NR3C1 or downstream effectors such as FKBP5 and TSC22D3 can abolish or modulate the dexamethasone response. For example, NR3C1 knockout cells fail to induce glucocorticoid-responsive genes, confirming its essential role. Knockout of TSC22D3 may reduce the anti-inflammatory effects of dexamethasone, as measured by cytokine production.
Point Mutation
Introducing point mutations in NR3C1 that mimic clinical variants can reveal how specific residues affect ligand binding, transactivation, or cofactor recruitment. For instance, mutations in the ligand-binding domain may cause glucocorticoid resistance. These models are valuable for studying personalized responses to dexamethasone.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags into the endogenous NR3C1 locus allows real-time tracking of receptor localization and interaction partners. Knock-in of disease-associated variants (e.g., in FKBP5) can model altered dexamethasone sensitivity in relevant cell types.
Overexpression
Overexpression of NR3C1 or its cofactors can enhance the dexamethasone response, while overexpression of dominant-negative mutants can suppress it. Overexpression of FKBP5 may reduce glucocorticoid sensitivity, providing a model for stress-related disorders. These approaches help dissect dosage effects and pathway crosstalk.
How EDITGENE Supports response to dexamethasone Research
Researchers studying response to dexamethasone-related genes often need to determine whether a candidate gene is causally involved in the cellular response to dexamethasone. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of genes annotated to GO:0071548.
Contact EDITGENE today to design your custom CRISPR model for response to dexamethasone research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PIK3CA Knockout Hep-G2 Cell Line | EDJ-KQ40 | Human | 5290 | Details Get a Quote |
| PIK3CA Knockout HEK293 Cell Line | EDJ-KQ518 | Human | 5290 | Details Get a Quote |
| FOXO3 Knockout HEK293 Cell Line | EDJ-KQ795 | Human | 2309 | Details Get a Quote |
| EDN1 Knockout HEK293 Cell Line | EDJ-KQ1485 | Human | 1906 | Details Get a Quote |
| EPO Knockout HEK293 Cell Line | EDJ-KQ1499 | Human | 2056 | Details Get a Quote |
| PCK2 Knockout HEK293 Cell Line | EDJ-KQ1544 | Human | 5106 | Details Get a Quote |
| GHSR Knockout HEK293 Cell Line | EDJ-KQ1797 | Human | 2693 | Details Get a Quote |
| CPS1 Knockout HEK293 Cell Line | EDJ-KQ1984 | Human | 1373 | Details Get a Quote |
| TAT Knockout HEK293 Cell Line | EDJ-KQ2159 | Human | 6898 | Details Get a Quote |
| UCP2 Knockout HEK293 Cell Line | EDJ-KQ2339 | Human | 7351 | Details Get a Quote |
| TDO2 Knockout HEK293 Cell Line | EDJ-KQ2779 | Human | 6999 | Details Get a Quote |
| POR Knockout HEK293 Cell Line | EDJ-KQ3088 | Human | 5447 | Details Get a Quote |
| CLDN1 Knockout HEK293 Cell Line | EDJ-KQ3729 | Human | 9076 | Details Get a Quote |
| TBX21 Knockout HEK293 Cell Line | EDJ-KQ9133 | Human | 30009 | Details Get a Quote |
| GBA1 Knockout HEK293 Cell Line | EDC90036 | Human | 2629 | Details Get a Quote |
Displaying Records 1 To 15 Of 72 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About response to dexamethasone
What is GO:0071548 response to dexamethasone?
GO:0071548 is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell or an organism as a result of a dexamethasone stimulus.
What genes are involved in response to dexamethasone?
Key genes include NR3C1, FKBP5, TSC22D3, NFKB1, IL6, TNF, and others that mediate glucocorticoid signaling and anti-inflammatory effects.
How is response to dexamethasone measured?
It can be measured by RNA-seq, qPCR, proteomics, cytokine profiling, and physiological assays such as intraocular pressure measurement.
What diseases are associated with response to dexamethasone?
Inflammatory diseases, tuberculous meningitis, allergic airway disease, metabolic disorders, hirsutism, and reproductive disorders.
What is the role of NR3C1 in response to dexamethasone?
NR3C1 encodes the glucocorticoid receptor, which binds dexamethasone and regulates transcription of target genes, initiating the response.
Can CRISPR be used to study response to dexamethasone?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can dissect the causal roles of genes in the dexamethasone response.
What is the dexamethasone suppression test?
It is a clinical test that uses dexamethasone to suppress cortisol production, assessing HPA axis function; abnormal responses can indicate endocrine disorders.
How does dexamethasone affect inflammation?
Dexamethasone suppresses pro-inflammatory cytokines and reduces inflammatory cell responses, as shown in allergic airway disease models.
Does dexamethasone affect insulin release?
In healthy subjects with low insulin response, dexamethasone treatment failed to increase arginine-induced insulin release, indicating context-dependent effects.
What cell models are available for studying response to dexamethasone?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for genes such as NR3C1, FKBP5, and TSC22D3.
Conclusion
GO:0071548 response to dexamethasone is a broad biological process that encompasses the diverse cellular and physiological changes triggered by this synthetic glucocorticoid. From transcriptional regulation by NR3C1 to clinical outcomes in inflammatory, metabolic, and reproductive diseases, the response is mediated by a complex network of genes and pathways. Understanding these mechanisms is essential for optimizing dexamethasone therapy and developing personalized treatments. CRISPR-based models and functional genomics approaches offer powerful tools to dissect the causal roles of individual genes in this response. EDITGENE's services support researchers in generating precisely engineered cell models to study GO:0071548 and accelerate discoveries in glucocorticoid biology.
References
- 1. Haribalaganesh R et al.. 2021. Assessment of differential intraocular pressure response to dexamethasone treatment in perfusion cultured Indian cadaveric eyes.. Sci Rep 11(1):605 PMID: 33436790
- 3. Whitworth LJ et al.. 2021. Elevated cerebrospinal fluid cytokine levels in tuberculous meningitis predict survival in response to dexamethasone.. Proc Natl Acad Sci U S A 118(10) PMID: 33658385
- 4. Keay SD et al.. 2001. Low-dose dexamethasone augments the ovarian response to exogenous gonadotrophins leading to a reduction in cycle cancellation rate in a standard IVF programme.. Hum Reprod 16(9):1861-5 PMID: 11527889
- 5. Grill V et al.. 1992. Dexamethasone treatment fails to increase arginine-induced insulin release in healthy subjects with low insulin response.. Diabetologia 35(4):367-71 PMID: 1516765
- 6. Elwood W et al.. 1992. Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats.. Am Rev Respir Dis 145(6):1289-94 PMID: 1595993
- 7. Preston AS et al.. 1988. Dexamethasone accelerates differentiation of A6 epithelia and increases response to vasopressin.. Am J Physiol 255(5 Pt 1):C661-6 PMID: 3189533
- 8. Givens JR et al.. 1975. Adrenal function in hirsutism I. Diurnal change and response of plasma androstenedione, testosterone, 17-hydroxyprogesterone, cortisol, LH and FSH to dexamethasone and 1/2 unit of ACTH.. J Clin Endocrinol Metab 40(6):988-1000 PMID: 166091
